Study guide
3.5 Substance-Related and Addictive Disorders
ANCC Psychiatric-Mental Health Nurse Practitioner PMHNP-BC
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Scientific Foundation
1.1 Neuroanatomy and Brain Function 1.2 Neurotransmitters and Synaptic Transmission 1.3 Neurodevelopmental and Neuroendocrine Mechanisms 1.4 Psychbehavioral Genetics and Epigenetics 1.5 Psychoneuroimmunology and Inflammatory Pathways 1.6 Psychopathology and Diagnostic Foundations 1.7 Evidence-Based Practice and Research Methodologies 1.8 Lifespan Growth and Development Theories 1.9 Health Promotion and Disease Prevention
2 Chapter 2: Advanced Practice Skills
2.1 Comprehensive Psychiatric Interview and Health History 2.2 Mental Status Examination (MSE) Concepts and Clinical Application 2.3 Physical and Neurological Assessment in Psychiatry 2.4 Diagnostic Laboratory and Imaging Interpretation 2.5 Suicide Risk Assessment and Safety Formulation 2.6 Violence and Homicide Risk Assessment 2.7 Substance Use, Intoxication, and Withdrawal Assessment 2.8 Cultural Competence and Social Determinants of Mental Health 2.9 Therapeutic Alliance and Clinical Communication 2.10 Functional and Diagnostic Risk Stratification
3 Chapter 3: Diagnosis and Treatment
3.1 Neurodevelopmental and Schizophrenia Spectrum Disorders 3.2 Bipolar and Related Disorders 3.3 Depressive Disorders 3.4 Anxiety Disorders, OCD, and Trauma-Related Disorders 3.5 Substance-Related and Addictive Disorders 3.6 Neurocognitive Disorders 3.7 Personality Disorders 3.8 Feeding/Eating, Sleep-Wake, and Somatic Symptom Disorders 3.9 Psychopharmacology Foundations: Antipsychotics and Mood Stabilizers 3.10 Psychopharmacology Foundations: Antidepressants, Anxiolytics, and Stimulants
4 Chapter 4: Psychotherapy and Related Theories
4.1 Cognitive Behavioral Therapy (CBT) and Dialectical Behavior Therapy (DBT) 4.2 Psychodynamic and Psychoanalytic Theories 4.3 Humanistic, Person-Centered, and Motivational Interviewing 4.4 Family and Group Psychotherapy Modalities 4.5 Integrative and Complementary Mental Health Approaches
5 Chapter 5: Ethics, Legal Principles, and Cultural Care
5.1 Patient Autonomy, Informed Consent, and Capacity 5.2 Involuntary Commitment and Patient Rights 5.3 Confidentiality, HIPAA, and Duty to Protect 5.4 Professional Scope of Practice and Prescriptive Authority 5.5 Malpractice, Liability, and Risk Management 5.6 Health Policy, Advocacy, and Mental Health Parity 5.7 Quality Improvement, Patient Safety, and Interprofessional Collaboration 5.8 Telepsychiatry, Technology, and Ethical Care Delivery
3.5 Substance-Related and Addictive Disorders
Key Takeaways Explain This Topic AI
Substance Use Disorder (SUD) severity is classified by DSM-5-TR criteria count over 12 months: Mild (2-3 criteria), Moderate (4-5 criteria), and Severe (6+ criteria).
Alcohol withdrawal can progress to Delirium Tremens (DTs) in 3-5% of patients, occurring 48-96 hours after cessation with autonomic hyperarousal, hallucinations, and a 1-5% mortality risk without benzodiazepine therapy.
Medication-Assisted Treatment (MAT) for Alcohol Use Disorder includes Naltrexone 50 mg daily (mu-opioid antagonist; contraindicated if LFTs > 3-5x ULN) and Acamprosate 666 mg TID (NMDA/GABA modulator; safe in liver disease, renal dose adjustment if CrCl 30-50 mL/min).
Opioid Use Disorder MAT utilizes Buprenorphine (partial mu-agonist; initiate at COWS score ≥ 8-12 to prevent precipitated withdrawal), Methadone (full mu-agonist), and Naltrexone 380 mg IM monthly.
Naloxone (0.4-2 mg IV/IM/intranasal) is a competitive mu-opioid antagonist that reverses life-threatening opioid overdose within 2-3 minutes by restoring respiratory drive.
Last updated: July 2026
Substance-Related and Addictive Disorders
Exam Tip: Understand the mechanisms and prescribing requirements for MAT. Methadone can only be dispensed for opioid addiction through specialized clinics, whereas Buprenorphine can be prescribed in office-based settings.
1. Substance Use Disorder (SUD) Framework
The DSM-5-TR integrates substance abuse and substance dependence into a single overarching diagnosis of Substance Use Disorder (SUD) . The disorder is defined by a cluster of cognitive, behavioral, and physiological symptoms indicating the individual continues using the substance despite significant substance-related problems. An additional addiction specifier encompasses behavioral addictions such as Gambling Disorder.
Criteria (11 items):
Taking the substance in larger amounts or over a longer period than intended.
Persistent desire or unsuccessful efforts to cut down.
Much time spent obtaining, using, or recovering.
Craving (a strong desire or urge to use).
Recurrent use resulting in failure to fulfill major role obligations.
Continued use despite social/interpersonal problems.
Giving up important social, occupational, or recreational activities.
Recurrent use in physically hazardous situations.
Continued use despite knowledge of having a physical or psychological problem caused by it.
Tolerance (need for increased amounts to achieve effect).
Withdrawal (characteristic syndrome or taking substance to relieve withdrawal).
Severity Specifiers:
- Mild: 2-3 symptoms
- Moderate: 4-5 symptoms
- Severe: 6 or more symptoms
Remission Specifiers: Early remission is 3-12 months without criteria (except craving); sustained remission is ≥12 months. Additional specifiers include "on maintenance therapy" (e.g., buprenorphine, methadone) and "in a controlled environment" (e.g., prison, locked residential rehab).
- 2. Alcohol Use Disorder
- Intoxication and Withdrawal
Intoxication: Slurred speech, incoordination, unsteady gait, nystagmus, impairment in attention or memory. Pathology may include disinhibition and aggressive behavior at lower BAC, progressing to somnolence and coma at high BAC (>0.30-0.40%).
Withdrawal: A medical emergency. Onset within 4-12 hours of last drink. Symptoms include autonomic hyperactivity (sweating, tachycardia >120 bpm, hypertension), hand tremor, insomnia, nausea, transient hallucinations (auditory or visual), anxiety, and generalized tonic-clonic seizures (typically 12-48 hours after last drink).
Delirium Tremens (DTs): A severe form of withdrawal occurring 48-72 hours after cessation, characterized by delirium, vivid hallucinations, severe autonomic instability (tachycardia, fever), and a mortality rate of 5-15% if untreated.
CIWA-Ar Monitoring: The Clinical Institute Withdrawal Assessment-Alcohol Revised scale scores 10 items (nausea, tremor, paroxysmal sweats, anxiety, agitation, tactile/auditory/visual disturbances, headache, orientation) on 0-7 scales. Score <8 = minimal withdrawal; 8-15 = moderate (consider pharmacotherapy); ≥15 = severe withdrawal (initiate benzodiazepine treatment).
Treatment of Acute Withdrawal:
Symptom-triggered Benzodiazepines based on CIWA-Ar scores. Lorazepam (1-2 mg) is preferred in hepatic dysfunction because it undergoes glucuronidation only (no oxidative metabolism, no active metabolites). Chlordiazepoxide (25-100 mg) and Diazepam (5-10 mg) have longer half-lives and smoother weaning but require intact hepatic metabolism.
Thiamine (Vitamin B1) 100 mg IV/IM for 3-5 days to prevent Wernicke-Korsakoff syndrome. Give parenteral thiamine as soon as possible, preferably before or with carbohydrate when feasible, but do not delay emergency glucose for a patient with hypoglycemia.
Folate supplementation and electrolyte correction (magnesium, potassium, phosphate).
Wernicke-Korsakoff Syndrome
Wernicke Encephalopathy: Acute neurological triad of ataxia, ophthalmoplegia (nystagmus, lateral rectus palsy), and confusion . Reversible with prompt thiamine administration.
Korsakoff Syndrome: Chronic, often irreversible anterograde and retrograde amnesia with confabulation (fabricated memories to fill memory gaps). Results from untreated or recurrent Wernicke encephalopathy; mammillary body degeneration on MRI.
Medication-Assisted Treatment (MAT) for Alcohol
Medication Mechanism Dosing Considerations
Naltrexone Mu-opioid antagonist; reduces dopamine reward of drinking 50 mg PO QD or 380 mg IM monthly (Vivitrol) Hepatotoxic; LFT monitoring; contraindicated in acute hepatitis/liver failure and concurrent opioid use
Acamprosate Modulates glutamate/GABA; restores post-acute withdrawal balance 666 mg PO TID Renally excreted (safe in liver disease); dose-adjust in renal impairment; avoid in severe CKD
Disulfiram Aldehyde dehydrogenase inhibitor; aversive conditioning 250 mg PO QD Severe reaction (flushing, N/V, tachycardia, hypotension) if alcohol consumed; requires motivated, supervised patient
- 3. Opioid Use Disorder
- Intoxication and Overdose
Intoxication: Euphoria followed by apathy, pupillary constriction (miosis), drowsiness, slurred speech, impairment in attention.
Overdose Triad: Pinpoint pupils, respiratory depression, coma. Fatal due to hypoxia and aspiration risk.
Overdose Reversal: Naloxone (Narcan) - a short-acting mu-opioid antagonist. Initial dose 0.4-2 mg IM/IN; repeat as needed. Naloxone has a shorter half-life (1-2 hours) than most opioids , so patients must be observed for re-sedation and recurrent respiratory depression; fentanyl analogs may require repeated dosing.
Opioid Withdrawal
Intensely uncomfortable but generally not life-threatening (unlike alcohol/benzo withdrawal). Onset varies by opioid half-life: heroin 6-12 hours, methadone 24-48 hours. Symptoms: Dysphoric mood, nausea/vomiting, muscle aches, lacrimation, rhinorrhea, pupillary dilation (mydriasis), piloerection ("cold turkey"), sweating, diarrhea, yawning, insomnia, low-grade fever.
Clinical Assessment: Use the Clinical Opiate Withdrawal Scale (COWS). Score ≥5-12 = mild, 13-24 = moderate, 25-36 = moderately severe, >36 = severe withdrawal.
MAT for Opioid Use Disorder
Buprenorphine: Partial mu-opioid agonist. High receptor affinity but low intrinsic activity. Has a "ceiling effect" for respiratory depression, making it safer than full agonists. Often combined with Naloxone (Suboxone) to deter IV diversion (naloxone is inactive sublingually). The federal X-waiver and its associated patient caps were repealed in 2023. A practitioner with standard DEA Schedule III authority may prescribe buprenorphine for OUD when permitted by state scope-of-practice law and other applicable requirements.
Methadone: Full mu-opioid agonist. Long half-life (24-36 hours) prevents withdrawal and cravings. Can prolong QTc; baseline and periodic ECG recommended, especially at doses >100 mg/day or with other QT-prolonging drugs. For OUD, methadone is dispensed or administered through a certified Opioid Treatment Program (OTP); current federal rules permit individualized take-home schedules rather than requiring observed daily dosing for every patient indefinitely.
Naltrexone: Mu-opioid antagonist. Blocks the effects of illicit opioids. The patient must be completely opioid-free for 7-10 days before initiation to avoid precipitated withdrawal . Available as monthly IM injection (Vivitrol, 380 mg) — useful for adherence.
4. Other Substances
Stimulants (Cocaine/Amphetamines): Intoxication presents with tachycardia, pupillary dilation, elevated BP, perspiration/chills, agitation, and potentially drug-induced psychosis (tactile hallucinations/"meth bugs"/formication). Withdrawal presents as a "crash" with severe dysphoria, fatigue, vivid unpleasant dreams, and hypersomnia/hyperphagia. No FDA-approved MAT for stimulant use disorder; treat with supportive care, CBT/contingency management, and antidepressants for depressive symptoms.
Sedative, Hypnotic, or Anxiolytic (Benzodiazepines): Intoxication resembles alcohol. Withdrawal is similar to alcohol withdrawal and carries a high risk of life-threatening seizures. Requires a slow taper (10% dose reduction per week) using a long-acting benzodiazepine (diazepam) or phenobarbital. Severe withdrawal may require inpatient detox.
Cannabis: Intoxication involves conjunctival injection (red eyes), increased appetite, dry mouth, and tachycardia. Withdrawal (often overlooked) begins within 1-3 days of cessation, peaks at 1 week, and includes irritability, anger, sleep difficulty, decreased appetite, and restlessness.
Hallucinogens (PCP, LSD, Psilocybin): Intoxication features perceptual disturbances (illusions, hallucinations), synesthesia, derealization; PCP specifically causes nystagmus (horizontal, vertical, rotatory), hypertension, violent behavior, analgesia, and hyperthermia. PCP intoxication is managed with a low-stimulation setting, supportive care, temperature and cardiovascular monitoring, and benzodiazepines for agitation or seizures. Urinary acidification is not recommended because it does not safely improve clearance and can worsen complications.
5. Clinical Vignette
A 42-year-old male with severe OUD (heroin, IV use) presents seeking help. He last used heroin 18 hours ago and has a COWS score of 22 (moderate withdrawal). He has hepatitis C with mildly elevated LFTs. Plan: Initiate buprenorphine/naloxone (Suboxone) 4 mg/1 mg sublingually once withdrawal is established (avoid precipitated withdrawal — confirm moderate withdrawal on COWS first). Provide naloxone rescue kit and overdose education. Counsel on hepatitis C treatment and HIV/HCV testing. Arrange behavioral counseling (CBT or contingency management). Avoid naltrexone until opioid-free for 7-10 days. Avoid methadone initiation unless referring to OTP.